Hangzhou Healsun Biopharm Co.,Ltd. was founded in 2015, a high-tech antibody/recombinant protein CRO/CDMO company, offering end-to-end service by multiple platforms from early drugability evaluation, stable cell line construction, culture medium customization, process development (including ADC), to pilot production, IND application and clinical production.

Healsun has Shanghai & Huangzhou two sites, over 220 employees. Shanghai R&D center has high-tech analytical platform and transient expression platform to support customers to do antibody humanization design, drugability evaluation and stability research from early stage for potential candidates’ predication and evaluation. Hangzhou headquarters has high performed cell line development platform to transform customers’ research into cost effective reality. The 250L, 500L, 1000L GMP production lines and fully automated final drug filling line facilitate path to clinical. The standard timeline is 8 months from DNA to toxicology batch delivery and 12-15 months to IND filing.